Skip to main content

Advertisement

Table 4 Odds ratio for risk of being HCV RNA negative among European American and African American injection drug users, by MBL2 secretor haplotype profile.

From: MBL2and Hepatitis C Virus Infection among Injection Drug Users

        Haplotype frequency estimates  
Secretor Haplotype Total HCV RNA Negative HCV RNA Positive P OR (95% CI)
European Americans
  -618 -289 -65 Ex1 -34 Ex1 -27 Ex1 -18      
HYPA G G C C G G 32.3% 29.2% 33.2% 0.24 referent
LYQA C G T C G G 21.2% 18.5% 22.1% 0.23 0.93 (0.58–1.51)
LXPA C C C C G G 19.5% 25.2% 17.7% 0.01 1.73 (1.10–2.74)
LYPB C G C C A G 12.9% 11.5% 13.3% 0.49 0.93 (0.53–1.64)
HYPD G G C T G G 6.5% 6.9% 6.4% 0.66 1.19 (0.59–2.39)
LYPA C G C C G G 5.1% 5.0% 5.1% 0.94 0.92(0.40–2.13)
LYQC C G T C G A 2.5% 3.9% 2.0% 0.08 3.27 (1.18–9.05)
Global score statistic 0.14  
African Americans
LYQA C G T C G G 27.3% 24.8% 28.0% 0.38 referent
LYQC C G T C G A 25.7% 27.0% 25.3% 0.69 1.24 (0.76–2.01)
LYPA C G C C G G 16.5% 18.4% 15.9% 0.49 1.24(0.70–2.21)
LXPA C C C C G G 15.4% 15.6% 15.4% 0.89 1.23 (0.69–2.18)
HYPA G G C C G G 10.7% 9.8% 10.9% 0.74 1.10 (0.57–2.12)
LYPB C G C C A G 3.4% 3.4% 3.4% 0.91 1.15 (0.44–3.01)
HYPD G G C T G G 1.0% 1.1% 1.0% 0.92 1.21 (0.23–6.29)
Global score statistic 0.98  
  1. Relative haplotype frequencies adjusted for sex, duration of injection drug use and HIV-1 serostatus.
  2. Haplotypes appear in order of descending haplotype frequencies among the comparison group stratified by race.
  3. P-value for LYPC among European Americans is not statistically signficant due to permutations based on small haplotype frequencies.
  4. The global score test evaluates differences between cases and controls in the overall haplotype distribution.